Abstracts from major epidemiological studies. Costs of complications were derived from published sources. From the government payer perspective, direct costs of diabetes complications and of SMBG were projected over patient lifetimes. Outcomes were discounted at 3% annually. RESULTS: Depending on type of treatment (diet/exercise, oral medications, or insulin), greater glycemic control with SMBG improved (discounted) QALE by 0.10 to 0.15 QALYs and increased total costs by €323 to €703 per patient. The resulting incremental cost-effectiveness ratios ranged from €3220 to €7276 per QALY gained, and were well within current willingness-to-pay limits. SMBG was most costeffective in the sub-group of patients being treated with oral antidiabetic medication. CONCLUSIONS: Within the three treatment regimens examined, the addition of SMBG was associated with increased glycemic control and with improved clinical and economic long-term outcomes. The incremental cost-effectiveness ratios were of magnitudes typically considered to indicate good value for money within the French health care setting. Additional comparative studies are needed to further assess Utilities and other standard outcomes associated with SMBG in patients with type 2 diabetes. (SMBG) can improve glycemic control (with HbA1c improvements of 0.3-0.6%, depending on treatment received). This in turn, can reduce risks of disease complications. Because monitoring supplies can have high acquisition costs, country-specific evaluations of SMBG cost-effectiveness are needed. The aim of this analysis was to estimate, within Germany, the cost-effectiveness of using SMBG. METHODS: A validated, published model for type 2 diabetes (The CORE Diabetes Model) was used to project improvements in quality-adjusted life expectancy (QALE), longterm costs and cost-effectiveness of SMBG. A series of Markov models simulated the progression of diabetes-related complications (cardiovascular, neuropathy, renal and eye disease). Transition probabilities and HbA1c-dependent adjustments came from major epidemiological studies. Costs of complications were derived from published sources. From the Government payer perspective, direct costs of diabetes complications and of SMBG were projected over patient lifetimes. Outcomes were discounted at 3% annually. RESULTS: Depending on type of treatment (diet/exercise, oral medications, or insulin), greater glycemic control with SMBG improved (discounted) QALE by 0.05 to 0.12 QALYs and increased total costs by €340 to €1227 per patient. The resulting incremental cost-effectiveness ratios ranged from €7558 to €10,447 per QALY gained, and were well within current willingness-to-pay limits. SMBG was most costeffective in the sub-group of patients being treated through diet and exercise. CONCLUSIONS: Within the three treatment regimens examined, the addition of SMBG was associated with increased glycemic control and with improved clinical and economic long-term outcomes. The incremental cost-effectiveness ratios were of magnitudes typically considered to indicate good value for money within the German health service setting. Additional comparative studies are needed to further assess Utilities and other standard outcomes associated with SMBG in patients with type 2 diabetes. 3 GWT TU Dresden, Dresden, Germany OBJECTIVES: To project the long-term clinical and cost outcomes of the addition of acarbose to existing treatments for type 2 diabetes patients in German, Spanish and Taiwanese settings. METHODS: Patient characteristics and acarbose treatment effects were based on clinical data from the MERIA meta-analysis. A published computer simulation model of diabetes was used to project long-term clinical and cost outcomes in patients receiving acarbose or placebo in addition to their existing treatment. It was used to project the life expectancy (LE), quality-adjusted life expectancy (QALE), cumulative incidence of diabetic complications and medical costs over the lifetime of the patients. Costs were calculated from a third-party health care payer perspective with unit costs derived from published sources (2004 Euro values). Costs and clinical benefits were discounted at 5% (Germany) and 3% (Spain, Taiwan) annually. RESULTS: Longterm projections indicated acarbose was associated with notable improvements in LE and QALE compared to placebo. For Germany, Spain and Taiwan incremental quality-adjusted life expectancy for acarbose compared to placebo were 0.21, 0.23 and 0.27 QALYs, respectively. Incremental cost (direct medical costs over patients' lifetimes) values of €134, €468 and €331 were estimated for the same three country settings. These values produced incremental cost-effectiveness ratios (ICERs) of €692 (Germany), €2199 (Spain), and €1291 (Taiwan) per QALY gained for acarbose versus placebo. The additional pharmacy costs associated with acarbose treatment were largely offset by reduced complication costs over patients' lifetimes. Acceptability curve analysis showed that with a willingness-to-pay of €20,000 per QALY gained, the probability of being costeffective was 95% in Germany, 93.5% in Spain and 96% in Taiwan for acarbose versus placebo. CONCLUSIONS: Acarbose was associated with reduced incidence of diabetes-related complications and improvements in LE and QALE and provides excellent value for money versus placebo over patients' lifetimes in the German, Spanish and Taiwanese settings. Type 2 diabetes poses significant clinical and economic burden to health care systems. It is therefore important to project economic and quality-adjusted effects of real-life clinical outcome improvements with different treatment options. This study aimed to evaluate such impacts when transferring type 2 patients on insulin glargine to insulin detemir. METHODS: Baseline and 3-month treatment effect data were collected from a subgroup of 260 patients with type 2 diabetes replacing insulin glargine with insulin detemir from a prospective, internationallybased observational trial. Baseline demographic data were: male 46.9%; mean age 63.7 years; duration of diabetes 9.9 years; HbA1C 7.83%; BMI 30.2 kg/m2. A validated simulation model of diabetes calculated gains in life years (LYG), quality-adjusted
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can improve glycemic control (with HbA1c improvements of 0.3-0.6%, depending on treatment received). This in turn, can reduce risks of disease complications. Because monitoring supplies can have high acquisition costs, country-specific evaluations of SMBG cost-effectiveness are needed. The aim of this analysis was to estimate, within Germany, the cost-effectiveness of using SMBG. METHODS: A validated, published model for type 2 diabetes (The CORE Diabetes Model) was used to project improvements in quality-adjusted life expectancy (QALE), longterm costs and cost-effectiveness of SMBG. A series of Markov models simulated the progression of diabetes-related complications (cardiovascular, neuropathy, renal and eye disease). Transition probabilities and HbA1c-dependent adjustments came from major epidemiological studies. Costs of complications were derived from published sources. From the Government payer perspective, direct costs of diabetes complications and of SMBG were projected over patient lifetimes. Outcomes were discounted at 3% annually. RESULTS: Depending on type of treatment (diet/exercise, oral medications, or insulin), greater glycemic control with SMBG improved (discounted) QALE by 0.05 to 0.12 QALYs and increased total costs by €340 to €1227 per patient. The resulting incremental cost-effectiveness ratios ranged from €7558 to €10,447 per QALY gained, and were well within current willingness-to-pay limits. SMBG was most costeffective in the sub-group of patients being treated through diet and exercise. CONCLUSIONS: Within the three treatment regimens examined, the addition of SMBG was associated with increased glycemic control and with improved clinical and economic long-term outcomes. The incremental cost-effectiveness ratios were of magnitudes typically considered to indicate good value for money within the German health service setting. Additional comparative studies are needed to further assess Utilities and other standard outcomes associated with SMBG in patients with type 2 diabetes. It was used to project the life expectancy (LE), quality-adjusted life expectancy (QALE), cumulative incidence of diabetic complications and medical costs over the lifetime of the patients. Costs were calculated from a third-party health care payer perspective with unit costs derived from published sources (2004 Euro values). Costs and clinical benefits were discounted at 5% (Germany) and 3% (Spain, Taiwan) annually. RESULTS: Longterm projections indicated acarbose was associated with notable improvements in LE and QALE compared to placebo. For Germany, Spain and Taiwan incremental quality-adjusted life expectancy for acarbose compared to placebo were 0.21, 0.23 and 0.27 QALYs, respectively. Incremental cost (direct medical costs over patients' lifetimes) values of €134, €468 and €331 were estimated for the same three country settings. These values produced incremental cost-effectiveness ratios (ICERs) of €692 (Germany), €2199 (Spain), and €1291 (Taiwan) per QALY gained for acarbose versus placebo. The additional pharmacy costs associated with acarbose treatment were largely offset by reduced complication costs over patients' lifetimes. Acceptability curve analysis showed that with a willingness-to-pay of €20,000 per QALY gained, the probability of being costeffective was 95% in Germany, 93.5% in Spain and 96% in Taiwan for acarbose versus placebo. CONCLUSIONS: Acarbose was associated with reduced incidence of diabetes-related complications and improvements in LE and QALE and provides excellent value for money versus placebo over patients' lifetimes in the German, Spanish and Taiwanese settings. Type 2 diabetes poses significant clinical and economic burden to health care systems. It is therefore important to project economic and quality-adjusted effects of real-life clinical outcome improvements with different treatment options. This study aimed to evaluate such impacts when transferring type 2 patients on insulin glargine to insulin detemir. METHODS: Baseline and 3-month treatment effect data were collected from a subgroup of 260 patients with type 2 diabetes replacing insulin glargine with insulin detemir from a prospective, internationallybased observational trial. Baseline demographic data were: male 46.9%; mean age 63.7 years; duration of diabetes 9.9 years; HbA1C 7.83%; BMI 30.2 kg/m2. A validated simulation model of diabetes calculated gains in life years (LYG), quality-adjusted life expectancy (QALE), cumulative complication incidences and total management costs (drug costs plus complications) over 10 years. The model combined a series of interdependent time-and state-based Markov sub-models of diabetes-related complications, incorporating 2nd order Monte-Carlo simulation. Future outcomes were discounted at 3% per annum (US Medicare perspective). Sensitivity analyses were performed. RESULTS: At follow-up, HbA1C was reduced 0.59% from baseline, fasting blood glucose (FBG) was more tightly controlled (−25 mg/dL), with mean weight loss of 0.78 kg. Daily dose remained stable upon replacing glargine (27.3 U vs. 23.8 U). Rate of all hypoglycaemia decreased by 728 events per 100 patient years from baseline, with major and nocturnal reduced by 26 and 208 events/100 patient years, respectively. Long-term projections indicated these clinical benefits increased LYG (0.07 years) and QALE (0.31 years). Direct medical costs were $2020 less per patient (10 years), largely due to reduced incidence rates of complications, predominantly renal and cardiovascular. CONCLUSION: Patients with type 2 diabetes may experience clinical outcome benefits when using insulin detemir compared to glargine. These benefits were projected to reduce treatment costs and increase QALE through a reduction of diabetes-related complications. CORECenter for Outcomes Research, A Unit of IMS, Allschwil, Switzerland OBJECTIVES: Evidence-based measures are necessary in medical decision-making when comparing modern therapy options with long-established treatments. As such, data from naturalistic settings provide important insight to use of such treatments in actual clinical practice. This study aimed to project real-life economic and clinical implications of converting type 2 diabetes patients on NPH basal-oral therapy to insulin detemir. METHODS: Pre-transfer, baseline and end-of-study data for 251 subjects converting from NPH ± orals to detemir ± orals were analyzed. Patients were an enrolled subgroup of a multi-national, prospective observational trial (51% male; mean age 61.5 years; diabetes duration 9 years; HbA1c 7.8%; BMI 30.9 kg/m2). Total treatment costs (annual drug plus complications), life years gained (LYG), quality-adjusted life expectancy (QALE), and cumulative complication incidences were assessed using a validated model of diabetes-related complications. Fifteen interconnected Markov sub-models employed second order Monte Carlo simulation and non-parametric bootstrapping (1000 × 1000) to estimate long-term outcomes (10 year horizon; US Medicare perspective), discounted at 3% per annum. Sensitivity analyses were performed. RESULTS: At 12 weeks post-transfer, mean absolute HbA1c was reduced 0.58%, with improved fasting blood glucose (−28 mg/dL) and weight reduction (0.87 kg). Observation period daily dose did not differ considerably to pre-transfer NPH (27.8 U vs. 25.7 U). Use of orals remained similar upon conversion. A reduced rate of all hypoglycaemia (pre-vs. posttransfer) was observed (−663 events/100 patient years), as were major and nocturnal episodes (39 and 429 events/100 patient years, respectively). Clinical benefits led to projected increases in LYG (0.07 years) and QALE (0.30 years), with associated total management costs reduced $2416 per patient, primarily from reductions in major hypoglycaemia and complication risks (notably ocular and cardiovascular). CONCLUSION: Improved glycaemic control and reduced hypoglycaemia were observed in patients with type 2 diabetes transferring from NPH-based therapy to detemir, generating projected improvements in quality-adjusted life expectancy and total costs. METHODS: Data were analyzed from 1321 patients who participated in a 12-week prospective observational trial (50.6% male; mean age 62.2 years; diabetes duration 6.5 years; HbA1c 8.49%; BMI 29.5 kg/m2). A published and validated simulation model of diabetes projected total treatment costs (annual drug plus complications), life years gained (LYG), quality-adjusted life expectancy (QALE), and complication incidences for patients commencing detemir versus those modelled to remain insulin naïve (10 year horizon). The model structure combines 15 interdependent Markov sub-models, simulating the progression of diabetes-related complications and utilizing second order Monte Carlo simulation to account statistical uncertainty at the patient and parameter levels. Outcomes were discounted at 3% per annum (US Medicare perspective). Sensitivity analyses were performed. RESULTS: Initiation of detemir generated a 1.29% mean reduction in HbA1c over 3 months, with improved fasting blood glucose (FBG; total (SD): −58 mg/dL (−8.2 mg/dL)), and no significant increase in the occurrence of hypoglycaemia. At follow-up, 16% of patients discontinued or reduced oral medications. Pharmacoeconomic modelling demonstrated detemir treatment to improve LYG (0.156 years) and QALE (0.173 years). Reduced major complication incidences were also estimated, including vascular, ocular, and renal events. An incremental cost-effectiveness ratio (ICER) of $657 per QALY gained was generated. An acceptability curve (willingness-to-pay of $50,000/QALY) revealed detemir to have a 95.5% chance of being cost-effective. CONCLUSION: Considerable short-term clinical benefits were observed among insulin-naïve type 2 patients initiating detemir. Long-term treatment with detemir was predicted to increase quality-adjusted outcomes and reduce diabetic complications in a cost-effective manner. 
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